Update on Stock Availability of Mounjaro® (tirzepatide)

Update 5 July 2024:

Eli Lilly Australia (Lilly) has recently notified the TGA that the 15mg dose of the Type 2 diabetes (T2D) medication Mounjaro® (tirzepatide) vial is currently unavailable. All other doses remain available at wholesalers in Australia in limited quantities. The supply situation is due to larger than expected demand and is not related to any safety, efficacy, or quality issues for Mounjaro.

Limited availability of all doses of Mounjaro are expected to continue until 31 August 2024. Information on supply of Mounjaro is available on the TGA medicines shortage reports database.(1) Healthcare professionals should consider the impact of limited product availability on patients when making treatment choices, particularly for new patient initiations.

Lilly is committed to future replenishment of all doses of Mounjaro. We recognise the inconvenience these disruptions may cause, and we thank you for your patience while we work to ensure the availability of Mounjaro in Australia. As part of our commitment to supplying Mounjaro for people with Type 2 diabetes in Australia, Lilly continues to invest and add manufacturing capacity around the world. We have commenced incretin production at our manufacturing facility in North Carolina, in the U.S., with additional actions and expansions at other sites around the globe.

For patients with T2D

We anticipate that patients could experience delays of several weeks in having their prescriptions filled, depending on location and wholesaler. Lilly does not have visibility of stock on hand at pharmacies.

We recognise these are challenging circumstances for patients on Mounjaro in Australia. Patients unable to fill their prescriptions are advised to consult with their Healthcare Professional regarding their treatment plan. In the instance that you miss a dose of Mounjaro, please consult your healthcare professional and follow the instructions contained in the Mounjaro Consumer Medicine Information.(2)

For prescribers & pharmacists :

Healthcare professionals requiring further medical or scientific information about Mounjaro may contact the Lilly Medical information team on 1800 454 559 / 1800 4 LILLY (operating hours Monday to Friday, 9 am – 5 pm AEDT).


  1. Australian Department of Health, Therapeutic Goods Administration, available at Medicine Shortages Information Initiative | Therapeutic Goods Administration (TGA), last accessed April 2024

  2. Mounjaro Consumer Medicine Information. Available at: Mounjaro Consumer Medicine Information. Accessed July 2024.

Mounjaro® is a registered trademark of Eli Lilly and Company.

Eli Lilly Australia Pty Limited, Level 9, 60 Margaret Street, Sydney, NSW 2000, Australia. ABN 39 000 233 922. Prepared July 2024. PP-TR-AU-0339.